Shares in 4d Pharma (LON:DDDD) have led a strong move away from the market average in recent weeks. On a relative price strength basis, the price is up by 98.8% against the market over the past three months. The last close price was 98...
DDDD — 4d Pharma Share Price
0.000.00%
Last Trade - 00:00HealthcareHighly SpeculativeSmall CapSucker Stock
- £146.04m
- £138.33m
- £0.53m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | 0.21 | 0.53 | n/a | 16.2 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for DDDD
Shares in 4d Pharma (LON:DDDD) have outperformed the market over the past three months, signalling optimism on the part of investors at a time of economic uncertainty. Based on relative price strength against the market, the company's...
Profile Summary
4D pharma plc (4D), formerly Schosween 18 Limited, is a United Kingdom-based pharmaceutical company focusing on developing various projects targeting new therapeutic areas. The principal activity of the Company is research and development of pharmaceutical products in new live biotherapeutic areas. The Company has developed its research to build MicroRx, which is a discovery methodology that is able to rationally select those bacteria that have a precise and evolved therapeutic effect. Its MicroRx methodology offers a pipeline of approximately 10 therapeutic programs covering autoimmune diseases, central nervous system (CNS) disorders and cancer. The Company uses MicroRx to develop its programs into the clinic and has approximately two programs in patient trials. The Company focuses on immune conditions, such as pediatric Crohn's, pediatric colitis and irritable bowel syndrome.
Directors
- Axel Glasmacher NEC (58)
- Duncan Peyton (51)
- John Beck (60)
- Alexander Stevenson (50)
- Glenn Dourado
- Paul Maier (73)
- David Norwood NED (51)
- Edgardo Baracchini
- Sandy Macrae
- Katrin Rupalla
- Last Annual
- December 31st, 2020
- Last Interim
- December 31st, 2020
- Incorporated
- January 10th, 2014
- Public Since
- February 18th, 2014
- No. of Employees
- 115
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 180,300,967
- Address
- 9 Bond Court, LEEDS, LS1 2JZ
- Web
- https://www.4dpharmaplc.com/
- Phone
- +44 1138950130
- Auditors
- RSM UK Audit LLP
Latest News for DDDD
Upcoming events for DDDD
Half Year 2021 4D Pharma PLC Earnings Release
Similar to DDDD
AVACTA ORD
London Stock Exchange
CLINIGEN ORD
London Stock Exchange
DESTINY PHARMA ORD
London Stock Exchange
ERGOMED ORD
London Stock Exchange
EVGEN PHARMA ORD
London Stock Exchange
FAQ
What is the 4d Pharma share price?
As of Today at 11:30 UTC, shares in 4d Pharma are trading at 81.00p. This share price information is delayed by 15 minutes.
How has the 4d Pharma share price performed this year?
Shares in 4d Pharma last closed at 81.00p and the price had moved by -8.99% over the past 365 days. In terms of relative price strength the 4d Pharma share price has underperformed the FTSE All Share Index by -25.3% over the past year.
What are the analyst and broker recommendations for 4d Pharma?
The overall consensus recommendation for 4d Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the 4d Pharma dividend yield?
4d Pharma does not currently pay a dividend.
Does 4d Pharma pay a dividend?
4d Pharma does not currently pay a dividend.
When does 4d Pharma next pay dividends?
4d Pharma does not currently pay a dividend.
How do I buy 4d Pharma shares?
To buy shares in 4d Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of 4d Pharma?
As of the previous close price of 81.00p, shares in 4d Pharma had a market capitalisation of £146.04m.
Where are 4d Pharma shares listed?
Here are the trading details for 4d Pharma:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: DDDD
What kind of share is 4d Pharma?
Based on an overall assessment of its quality, value and momentum 4d Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a 4d Pharma share price forecast for 2021?
The analyst consensus target price for shares in 4d Pharma is 405.00p. That is 400% above the last closing price of 81.00p.
Analysts covering 4d Pharma currently have a consensus Earnings Per Share (EPS) forecast of -£0.14 for the next financial year.
What is the trend in the 4d Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 4d Pharma. Over the past six months, its share price has underperformed the FTSE All Share Index by -49.97%.
As of the last closing price of 81.00p, shares in 4d Pharma were trading -24.55% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the 4d Pharma PE Ratio?
We are not able to find PE ratio data for 4d Pharma.
Who are the key directors of 4d Pharma?
4d Pharma's management team is headed by:
- Axel Glasmacher - NEC
- Duncan Peyton -
- John Beck -
- Alexander Stevenson -
- Glenn Dourado -
- Paul Maier -
- David Norwood - NED
- Edgardo Baracchini -
- Sandy Macrae -
- Katrin Rupalla -
Who are the major shareholders of 4d Pharma?
We do not have data on 4d Pharma's shareholders